Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10969121 | Vaccine | 2011 | 8 Pages |
Abstract
In double-blind trials in Bangladesh, 88 adults, and 79 children (8-10 years) were randomized to receive either a single oral dose of 1Â ÃÂ 104, 1Â ÃÂ 105 or 1Â ÃÂ 106Â CFU of SC602 (a live, attenuated Shigella flexneri 2a strain vaccine) or placebo. In the adult outpatient 1Â ÃÂ 106 CFU group, severe joint pain and body aches were reported by one and two vaccinees respectively. In the adult inpatient trial, SC602 was isolated from 3 volunteers, pre-vaccination antibody titers were high, and fourfold increases in serum IgG anti-LPS responses were observed in 2 of 5 subjects of the 1Â ÃÂ 106Â CFU group. None of the volunteers developed diarrhea. Overall, SC602 was found to be associated with minimal vaccine shedding, minimal reactogenicity, no transmission risk, and low immune stimulation.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Kazi Mizanur Rahman, Shams El Arifeen, K. Zaman, Mahbubur Rahman, Rubhana Raqib, Mohammad Yunus, Nazma Begum, Md. Shaheenul Islam, Badrul Munir Sohel, Muntasirur Rahman, Malabi Venkatesan, Thomas L. Hale, Daniel W. Isenbarger, Philippe J. Sansonetti,